Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Nom du journal : Front Endocrinol (Lausanne)
Année : 2024
Volume : 15
Page de départ : 1403687
